Results 1 to 10 of about 1,626,261 (197)

Eloralintide (LY3841136), a Novel Amylin Receptor Agonist for the Treatment of Obesity: From Discovery to Clinical Proof of Concept [PDF]

open access: yesMolecular Metabolism
Objectives: Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity.
Libbey O'Farrell   +2 more
exaly   +4 more sources

Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications. [PDF]

open access: yesJ Diabetes Investig
ABSTRACT Type 1 diabetes is defined by immune‐mediated beta‐cell failure and dependence on exogenous insulin. That definition is correct, but it may not fully describe many people seen in current clinical practice. Overweight and obesity are now common in type 1 diabetes, leading to variable combinations of high insulin requirement, hypertension ...
Bloomgarden Z.
europepmc   +2 more sources

Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning. [PDF]

open access: yesDiabetes Obes Metab
ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Sztanek F   +3 more
europepmc   +2 more sources

Amylin Receptor Ligands Reduce the Pathological Cascade of Alzheimer's Disease [PDF]

open access: yesNeuropharmacology, 2017
Thor D Stein, Wei Qiao Qiu, Max Wallack
exaly   +2 more sources

Injectable Peptide‐Based Functional Amyloid Hydrogels as Tunable Depots for Sustained Drug Delivery

open access: yesAdvanced Science, EarlyView.
An injectable and tunable peptide‐based functional amyloid hydrogel provides sustained insulin release while preserving insulin stability and bioactivity. The hydrogel enables prolonged glycemic regulation in vivo, exhibits excellent biocompatibility, and shows no detectable IAPP and α‐Syn heterologous cross‐seeding, highlighting its potential as a ...
Ranjit Shaw   +4 more
wiley   +1 more source

Non‐Nutritive Artificial Sweeteners Aspartame and Acesulfame‐K Ameliorate Metabolic Dysfunction‐Associated Steatotic Liver Disease in Male Ldlr−/− Mice

open access: yesiNew Medicine, EarlyView.
ABSTRACT Aspartame and acesulfame‐K are commonly used non‐nutritive artificial sweeteners, but their impacts on cardiovascular disease and metabolic dysfunction‐associated fatty liver disease (MASLD) are unclear. In this study, we evaluated the impacts of aspartame and acesulfame‐K on MASLD and atherosclerosis in male Ldlr−/− mice fed an AMLN diet ...
Jingjing Xu   +3 more
wiley   +1 more source

Hepatocyte‐Centered Regulation of MASH Fibrosis: From Animal Models to Molecular Mechanisms and Targeted Therapies

open access: yesiNew Medicine, EarlyView.
This review highlights hepatocytes as active regulators of MASH fibrosis through secreted proteins, metabolites, and extracellular vesicles that modulate hepatic stellate cell activation. These hepatocyte–stellate cell communication pathways provide a mechanistic framework for developing targeted antifibrotic therapies, including hepatocyte‐directed ...
Eui Jung Jung, Xiaobo Wang
wiley   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Home - About - Disclaimer - Privacy